Synchrony Medical Inc.

Based in the US, Synchrony Medical Inc. develops innovative airway clearance systems aimed at enhancing respiratory health for patients suffering from chronic lung diseases. Their technology focuses on effective mucus clearance to improve patient outcomes. Synchrony Medical Inc.

is focused on creating solutions for respiratory health. Founded in 2020 in Jersey City, US, the company has successfully completed one funding round. In August 2025, Synchrony Medical Inc. raised USD 4.

3 million in seed funding led by Edge Medical Ventures, with participation from New Jersey Economic Development Authority, Broadfin Capital, and Consensus Business Group The total amount raised to date is USD 4. 3 million. The company was founded by individuals whose prior experience is not specified. LibAirty specializes in an innovative airway clearance system designed to improve respiratory health for patients with chronic lung diseases.

The core product, the LibAirty Airway Clearance System, synchronizes controlled breathing with targeted chest compressions to provide effective relief by clearing mucus from the lungs. This system is inspired by Autogenic Drainage techniques and is engineered to guide patients through the breathing process during treatment sessions, effectively mobilizing secretions from small to larger airways. By directing airflow to hard-to-reach areas of the lungs, LibAirty aims to enhance patient outcomes and reduce the incidence of lung infections. The device is primarily marketed to healthcare providers, hospitals, and patients across the United States, addressing the needs of individuals suffering from conditions such as bronchiectasis and other chronic respiratory diseases.

LibAirty generates revenue through direct sales of its airway clearance systems and potentially through partnerships with healthcare facilities and professionals. The company's flagship product is the LibAirty Airway Clearance System, which is sold to both healthcare providers and end-users, ensuring accessibility for patients requiring at-home treatment. Transactions typically involve healthcare providers purchasing the device for patient use, where a structured pricing model may apply based on individual contracts or agreements. The company’s focus on enhancing patient satisfaction and therapeutic effectiveness positions it favorably within the market, potentially leading to repeat business from healthcare providers and positive referrals from satisfied patients.

In August 2025, Synchrony Medical Inc. raised USD 4. 3 million in venture funding, which will be utilized to grow its U. S.

operations, advance clinical studies, and further develop its airway clearance technology. The company aims to expand its market presence by introducing new products designed for enhanced respiratory treatment and targeting new geographic regions, although specific timelines and locations for the expansion have not been disclosed.